Pharmacokinetics and pharmacodynamics of heparin during hemodialysis: interpatient and intrapatient variability. 1990

R J Kandrotas, and P Gal, and J B Douglas, and J Deterding
Department of Pharmacy, Moses H. Cone Memorial Hospital, Chapel Hill, North Carolina.

Heparin pharmacokinetics and pharmacodynamics were studied in 17 patients undergoing hemodialysis, once a week for 4 weeks in order to evaluate intrapatient variability over time. A single bolus injection of heparin was administered directly into the circulation immediately prior to the start of hemodialysis in doses ranging from 3000 to 12,000 U. Blood samples were obtained to determine activated coagulation times (ACT) and heparin concentrations (HC). Combined zero- and first-order elimination was seen in each of the 4 weeks. The half-life of heparin decreased from beginning to end of hemodialysis during each week, with the percentage of decrease from the start of dialysis ranging from 70-74%, indicating concentration-dependent elimination. Since the zero-order component did not appear to be clinically significant, first-order elimination was assumed. A linear decline in ACT over the time of the dialysis period was also seen during each week. A profile of ACT versus HC was generated for each patient as well as for the mean data to assess the relationship of HC to response. An excellent correlation was found for both individual patient data and mean data. In the third week the patients were randomized to receive standard treatment or an individualized dose. They were then crossed over to the opposite group in the fourth week to see if this relationship between ACT and HC would be useful in predicting heparin dose. These profiles were used to individualize the dose during either the third or fourth week of the study. No significant differences were noted between actual and predicted ACT. A significant degree of interpatient variability was demonstrated.(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006435 Renal Dialysis Therapy for the insufficient cleansing of the BLOOD by the kidneys based on dialysis and including hemodialysis, PERITONEAL DIALYSIS, and HEMODIAFILTRATION. Dialysis, Extracorporeal,Dialysis, Renal,Extracorporeal Dialysis,Hemodialysis,Dialyses, Extracorporeal,Dialyses, Renal,Extracorporeal Dialyses,Hemodialyses,Renal Dialyses
D006493 Heparin A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts. Heparinic Acid,alpha-Heparin,Heparin Sodium,Liquaemin,Sodium Heparin,Unfractionated Heparin,Heparin, Sodium,Heparin, Unfractionated,alpha Heparin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor

Related Publications

R J Kandrotas, and P Gal, and J B Douglas, and J Deterding
January 1987, Clinical pharmacology and therapeutics,
R J Kandrotas, and P Gal, and J B Douglas, and J Deterding
June 2002, Therapeutic drug monitoring,
R J Kandrotas, and P Gal, and J B Douglas, and J Deterding
April 2012, Therapeutic drug monitoring,
R J Kandrotas, and P Gal, and J B Douglas, and J Deterding
May 1992, Clinical pharmacokinetics,
R J Kandrotas, and P Gal, and J B Douglas, and J Deterding
January 2012, American journal of nephrology,
R J Kandrotas, and P Gal, and J B Douglas, and J Deterding
November 2010, Clinical journal of the American Society of Nephrology : CJASN,
R J Kandrotas, and P Gal, and J B Douglas, and J Deterding
May 2008, American journal of kidney diseases : the official journal of the National Kidney Foundation,
R J Kandrotas, and P Gal, and J B Douglas, and J Deterding
March 1987, American journal of diseases of children (1960),
R J Kandrotas, and P Gal, and J B Douglas, and J Deterding
January 1988, Agents and actions. Supplements,
R J Kandrotas, and P Gal, and J B Douglas, and J Deterding
August 2017, Therapeutic drug monitoring,
Copied contents to your clipboard!